Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study

Olga Chatzis1†, Stephanie Darbre2†, Jérôme Pasquier3, Pascal Meylan4, Oriol Manuel5,6, John David Aubert7, Maja Beck-Popovic8, Stavroula Masouridi-Levrat9, Marc Ansari10, Laurent Kaiser11,12, Klara M. Posfay-Barbe1 and Sandra A. Asner1,5,13*

Abstract

Background: Respiratory syncytial virus (RSV) is associated with significant mortality rates amongst hematopoietic stem cell transplant (HSCT) recipients, with less known about other immunocompromised patients.

Methods: Ten-year retrospective cohort study of immunocompromised patients presenting with RSV disease documented at University Hospitals of Lausanne and Geneva. Severe RSV-related outcomes referred to RSV documented respiratory conditions requiring hospital admission, presenting as lower respiratory tract infection (LRTI) or pneumonia. We used multivariable logistic regression to assess clinical and laboratory correlates of severe RSV disease.

Results: From 239 RSV-positive immunocompromised in and out-patients 175 were adults and 64 children of whom 111 (47.8%) presented with LRTI, which resulted in a 38% (89/239) admission rate to hospital. While immunocompromised children were more likely to be admitted to hospital compared to adults (75% vs 62.9%, \( p = 0.090 \)), inpatients admitted to the intensive care unit (17/19) or those who died (11/11) were mainly adults. From multivariable analyses, adults with solid tumors (OR 5.2; 95% CI: 1.4–20.9; \( P = 0.015 \)) or those requiring chronic immunosuppressive treatments mainly for rheumatologic conditions (OR 4.1; 95% CI: 1.1–16.0; \( P = 0.034 \)) were significantly more likely to be admitted to hospital compared to hematopoietic stem cell (HSCT) recipients. Bacterial co-infection was significantly and consistently associated with viral LRTI and pneumonia.

Conclusions: From our findings, RSV-related disease results in a significant burden among adults requiring chronic immunosuppressive treatments for rheumatological conditions and those with solid tumors. As such, systematic screening for respiratory viruses, should be extended to other immunocompromised populations than HSCT recipients.

Background

Respiratory syncytial virus (RSV), a single-stranded virus of the paramyxoviridae family, is the most important viral etiologic agent of lower respiratory tract infection (LRTI) in infants and young children worldwide [1, 2]. Although mortality rates in healthy infants with RSV pneumonia are less than 0.5%, they can reach up to 60% in untreated immunocompromised children or adults. The burden of RSV infections is well described in adult hematopoietic stem cell transplant (HSCT) recipients in whom progression from upper respiratory tract infection (URTI) to LRTI is frequent (40 to 60% of cases) with mortality rates approaching 80%. Recent evidence also supports immunomodulatory effects of RSV infections among lung transplant recipients, in whom a significant association between the development of chronic lung allograft dysfunction (CLAD) and RSV infections has recently been reported [3–8].

To date, published reports of RSV infections in immunocompromised patients have primarily focused on
adult HSCT recipients with much less known in other adult and pediatric immunocompromised settings [3–7].

Given the lack of information on the burden of RSV infections in other immunocompromised adult and pediatric populations than HSCT recipients, it is essential to obtain further information on the risk factors and outcomes of severe RSV disease among immunocompromised patients. This is important to optimize the prevention of severe RSV disease in this patient population.

This primary objective of this study was to describe the burden and characteristics of RSV infections in a broad population of immunocompromised adults and children. Our secondary objective, was to identify the risk factors for severe RSV infections defined as hospital admission, LRTI and pneumonia.

**Methods**

**Study population and definitions**

From January 1, 2005 to December 31, 2014, we conducted a multi-center observational study of children and adults presenting with an immunodeficiency state who presented with an RSV-URTI or LRTI in an ambulatory setting or upon or during their admission to the University hospitals of Lausanne and Geneva, Switzerland. RSV-positive patients were identified from Laboratory records. Clinical and laboratory data on RSV-positive immunocompromised adults and children were collected retrospectively with the assistance of hospital medical records. All children less than 18 years of age and adults presenting with at least one of the following conditions were included: allogeneic or autologous HSCT recipients, solid organ transplant (SOT) recipients, patients on cancer chemotherapy or long-term immunosuppression for any chronic disease, which included mostly patients with an underlying rheumatologic condition and those with Connective Tissue Disease (CTD) (Additional file 1: Table S1); and primary immunodeficiency disease (PID). Immunocompromised children with other comorbidities qualifying for RSV prophylaxis based on current Swiss guidelines [8] and patients with human immunodeficiency virus (HIV) were excluded. We defined RSV as detection of RSV in upper respiratory secretions together with symptoms only involving the upper respiratory tract and LRTI as any RSV-positive patient associated with cough, tachypnea and any respiratory distress or wheezing. Pneumonia was defined as any of the above LRTI symptoms with pulmonary infiltrates reported by a radiologist on chest radiography and the exclusion of other causes as defined elsewhere [9, 10]. Acute-respiratory-tract infection (ARTI)-attributable hospital admission included patient admitted for respiratory symptoms with concomitant documentation of RSV in a respiratory samples. Severe neutropenia was defined as an absolute neutrophil count (ANC) < 500 cells/μl and severe lymphopenia as an absolute lymphocyte count (ALC) < 100 cells/μl [11]. Approval was obtained from the Research Ethics Boards at University hospitals of Lausanne and Geneva.

**Collection of clinical information**

Information on patient demographic variables such as age, gender, type of immunosuppression, bacterial and viral co-infection, median ANC or ALC counts, oral ribavirin or palivizumab treatments were all abstracted from health records. Primary outcome referred to acute respiratory tract infection (ARTI)-attributable hospital admission. Secondary outcomes consisted of the documentation of LRTI or pneumonia, intensive care unit (ICU) admission and RSV-contributed mortality within 30 days of the diagnosis of RSV infection. RSV-attributable admission to the intensive care unit (ICU) was defined as a documented RSV disease requiring admission to the ICU. Overall mortality referred to death from any cause whereas RSV-contributed mortality was defined as a persistent or progressive RSV infection with respiratory failure documented at the time of death [12]. Each case was adjudicated by 2 members of the study team.

**Virology studies**

From 2005 to 2013, nasopharyngeal specimens, bronchoalveolar lavage (BAL) fluids and sputum samples were examined by a two-step reverse transcriptase polymerase chain reaction (RT-PCR) assay, targeting RSV A and B. This assay is extensively validated at the Laboratory of Virology, University Hospitals Geneva. In addition, specimens collected from children, which required immediate identification for cohorting purposes, were tested by a rapid antigen assay for RSV (RSV Respi-Strip, Coris Biocentre) [13, 14]. A commercial one-step PCR FTD Respiratory pathogens 21 (ref.FTD.-53/12) from FastTrack Diagnostics (Luxembourg) (used at University hospitals Geneva since 2013) and the Cepheid Xpert Flu/RSV (used at University hospital Lausanne since 2015) further replaced molecular and rapid antigen assays [15, 16]. A patient was defined as being RSV-positive if any specimen was positive by any diagnostic method (antigen assay or any of the above listed molecular assay). Multiple simultaneous virus infections (herein referred to as viral co-infection) were those in which two or more virus pathogens were detected from the same respiratory sample. Bacterial co-infection was defined as the presence of any bacterial pathogen, identified by culture from blood or respiratory samples upon initial consultation with respiratory symptoms or within 30 days of their initial consultation in association with a documented viral infection. We excluded children if blood culture isolates were considered to be contaminants based on international guidelines [17].
Statistical analyses

Standard descriptive and comparative statistics (the Fish-er’s exact test for categorical variables and the Mann-Whitney U test for continuous variables) were used on data categorized by age groups (children under 18 years of age and adults) and in and outpatients. For all statistical testing, only the first RSV-positive nasopharyngeal swab was included in cases with multiple RSV-positive swabs within the same patient because these samples cannot be considered independent. Univariable and multivariable logistic regression were used to assess clinical and laboratory correlates of ARTI-attributable hospital admission, LRTI and pneumonia with stratified analyses for children and adults. Predictor variables included different immunosuppressive categories, age, bacterial infection, and ALC for all patients and the adult subgroup whereas only bacterial co-infection and ALC were included in the children subgroup given the small number of observations. Statistically significant predictors in univariable analyses were included in multivariable analyses [18]. All analyses were conducted by complete case analyses, excluding all patients with missing values for any dependent or independent variables. We evaluated next the robustness of the estimates related to the potential differences in disease severity described for i) HSCT recipients infected with RSV within 2 years of transplantation; ii) patients who presented with viral co-infections and iii) patients detected RSV-positive by molecular assays solely. Therefore, we performed three post hoc sensitivity analyses for primary and secondary outcomes: one in which HSCT recipients infected with RSV after two years from their transplantation were excluded, another one excluding all 52 patients with viral coinfections and one excluding 12 children detected RSV-positive by rapid antigen assays only. Two sided tests were performed, and a P value < 0.05 was considered to be statistically significant. Data were analyzed using SPSS statistical software (version 20.0, SPSS Inc., Chicago, IL, USA), SAS and R (version 3.3.3, R Foundation for Statistical Computing, Vienna, Austria).

Results

Descriptive characteristics of study subjects

Three thousand two hundred and twenty-three RSV-positive patients (4,605 positive RSV samples) of whom 239 (7.4%) were eligible RSV-positive immunocompromised subjects (64 (26.8%) children and 175 adults (73.2%) (Additional file 1: Figure S1). From all patients, HSCT recipients (N = 67; 28.0%) and SOT recipients (N = 63; 26.4%) were the most common immunosuppressive conditions included. Most of the 64 children, 35 (54.7%) males, with a median age of 4.9 years (interquartile range [IQR] 3.2–7.7) presented with leukaemia or lymphoma (N = 29; 45.3%), whereas HSCT (N = 59, 33.7%) and SOT (N = 58, 33.1%) were the most common immunosuppressive conditions documented among the 175 adults (Table 1).

Proportion of RSV-positive specimens, bacterial and viral co-infections

RSV was detected positive from 202 (84.5%) nasopharyngeal (NP) swabs and 35 (15%) BAL, of which 25 (28.6%) were collected from patients with pneumonia. Two hundred and twenty-seven patients (95%) were detected by molecular assays and 12 (5%) by rapid antigen assays. From all patients, 36 (15.1%) presented with a documented bacterial co-infection, of whom 29 (80.6%) with bacteremia and 7 (19.4%) with bacterial pneumonia documented from BAL. From the 11 patients who died, only 3 (27.3%) presented with a bacterial co-infection (S. aureus, Stenotrophomonas maltophilia and Legionella pneumophila) documented from BAL. 52 (21.8%) patients presented with a viral co-infection of whom 10 (19.2%) had more than two viruses detected. The most common viral co-infections were human rhinovirus/enterovirus-RSV (16/42; 38.1%), parainfluenza (PIV)-RSV (6/42; 14.3%) and influenza (FLU)-RSV (6/42; 14.3%) (Table 1).

Clinical outcomes

From all immunocompromised subjects, 89 (37.2%) (N = 58; 34.1% adults; N = 31; 48.4% children; p = 0.090) were admitted to hospital for their RSV infection with a median duration of stay of 5 days (IQR: 0–18 days). From those 89, 19 (21.3%) patients were admitted to intensive care of whom 6 (31.6%) presented with chronic disease requiring underlying immunosuppressive therapy, 4 (21.1%) with solid tumors and 4 (21.1%) with HSCT. Patients admitted to the ICU, requiring mechanical ventilation and those who died were almost all adults. Likewise immunocompromised adults presented with significantly higher rates of pneumonia (36.9% vs. 18.8%; p = 0.008) compared to immunocompromised children. Furthermore, all 11 adults who died within 30 days of their RSV-attributable admission, presented with pneumonia despite ribavarin (N = 6, 54.5%) or palivizumab (N = 2, 18.2%) administration. Most of those 11 patients, median age of 64.6 years (IQR 34.1–73.9), were HSCT recipients (N = 4, 36.4%) or presented with lymphoma/leukemia (N = 3, 27.3%) or solid tumors (N = 3; 27.3%) (Table 2).

Predictors of hospitalization

From multivariable analyses, we identified that patients with leukaemia/lymphoma (odds ratio [OR] 3.9; 95% confidence interval [CI]: 1.7–9.7; p = 0.002), solid tumors (OR 7.4; 95% CI: 2.7–21.9; p < 0.001) or those requiring chronic immunosuppression mainly for vasculitis (OR 9.5; 95% CI: 3.3–30.2 P < 0.001) when compared to HSCT,
### Table 1 Baseline characteristics of immunocompromised patients with RSV infection

| Variable; number (%) unless indicated otherwise | CHILDREN N = 64 | ADULTS N = 175 | TOTAL N = 239 |
|------------------------------------------------|----------------|---------------|--------------|
|                                                   | INPATIENTS | OUTPATIENTS | INPATIENTS | OUTPATIENTS | INPATIENTS | OUTPATIENTS |
|                                                   | N = 48 | N = 16 | N = 107 | N = 68 | N = 155 | N = 84 |
| < 2 years                                         | 11 (23) | 2 (12.5) | 60.5 (48–70.6) | 50.8 (37.3–59.4) | 79 (51) | 43 (51.2) |
| 2–5 years                                         | 13 (27.1) | 7 (43.75) | 53 (49.5) | 34 (20) | 79 (51) | 43 (51.2) |
| 5–18 years                                        | 24 (50) | 7 (43.75) |
| Age (years) median (IQR)                          | 4.9 (2.7–7.4) | 47 (3.7–8.8) | 60.5 (48–70.6) | 50.8 (37.3–59.4) | 79 (51) | 43 (51.2) |
| Male                                              | 26 (54.2) | 9 (56.3) | 53 (49.5) | 34 (20) | 79 (51) | 43 (51.2) |
| HSCT                                               | 2 (4.2) | 6 (37.5) | 24 (22.4) | 35 (51.5) | 26 (16.8) | 41 (48.8) |
| Autologous                                        | 0 | 0 | 9 (8.4) | 1 (1.5) | 9 (5.8) | 11.1 |
| Allogeneic                                        | 0 | 8 (100) | 15 (14) | 34 (50) | 24 (15.5) | 45 (53.6) |
| Matched                                           | 0 | 3 (18.8) | 5 (4.7) | 19 (28) | 5 (3.2) | 22 (26.2) |
| Mismatched                                        | 0 | 0 | 1 (1) | 0 | 1 (0.6) | 0 |
| Unrelated                                         | 2 (4.2) | 1 (6.3) | 9 (8.4) | 15 (22.1) | 11 (7.1) | 16 (19) |
| SOT                                               | 3(6.3) | 2 (12.5) | 32 (30) | 26 (38.2) | 35 (22.6) | 28 (33.3) |
| Leukaemia /lymphoma                               | 23 (47.9) | 6 (37.5) | 18 (16.8) | 3(4.4) | 41 (26.5) | 9 (10.7) |
| Solid tumor                                       | 9 (18.8) | 2 (12.5) | 15 (14) | 11.5 | 24 (15.5) | 3(3.6) |
| Chronic immuno-suppression                        | 6 (12.5) | 0 | 18 (16.8) | 2 (3.0) | 24 (15.5) | 2(2.4) |
| PID                                               | 5 (10.4) | 0 | 0 | 1 (1) | 5 (3.2) | 1(1.2) |
| GVHD among allogeneic HSCT recipients             | 1 (2.1) | 4 (25) | 9 (8.4) | 21 (30.9) | 10 (6.5) | 25 (29.8) |
| Bacterial co-infection                            | 8 (16.7) | 1 (6.3) | 25 (23.4) | 2 (3) | 33 (21.3) | 3(3.6) |
| Viral co-infection                                | 12 (25) | 6 (37.5) | 22 (20.6) | 12 (17.7) | 34 (21.9) | 18(21.4) |
| ANC, median, (IQR)                                | 1.1 (0.5–3.1) | 1.7 (1.6–4.2) | 4.6 (1.4–8.1) | 3.5 (2.6–5.3) | 3.4 (0.9–6.7) | 3.3 (2.3–5.3) |
| ALC, median (IQR)                                 | 0.6 (0.2–1.9) | 0.7 (0.1–1.1) | 1.1 (0.4–1.9) | 0.7 (0.2–1.4) | 1.1 (0.6–1.9) |
| Oral ribavirin treatment                          | 1 (2.1) | 1 (6.3) | 24 (22.4) | 12 (17.6) | 25 (16.1) | 13 (15.5) |
| Palivizumab treatment                             | 2 (4.2) | 0 | 7 (6.5) | 1 (1.5) | 9 (5.8) | 11(1.2) |

Absolute neutrophil counts (ANC), Absolute lymphocyte counts (ALC), Graft vs. host disease (GVHD), Hematopoietic stem cell transplant (HSCT), Interquartile range (IQR), Primary Immunodeficiency Disease (PID), Solid Organ Transplant (SOT)

Number of missing values: Children outpatients: ANC N = 1, ALC N = 1; adult inpatients ANC N = 5, ALC N = 5; adult outpatients ANC N = 13, ALC N = 13

### Table 2 Clinical outcomes of immunocompromised patients with RSV infection

| Variable; Number; (%) unless indicated otherwise | Children (N = 64) | Adult (N = 175) | p value | Total (N = 239) |
|-------------------------------------------------|-----------------|----------------|--------|---------------|
| All-cause admission to hospital (adults: 5 missing values) | 48 (75.0) | 107 (62.9) | 0.090 | 155 (66.2) |
| ARTI-attributable hospital admission<sup>a</sup> (adults: 5 missing values) | 31 (48.4) | 58 (34.1) | 0.050 | 89 (38.0) |
| Length of hospital stay (mean (SD)<sup>b</sup>) | 5 (3.5) | 9 (12.0) | < 0.001 | 7 (9.0) |
| Admission to the ICU<sup>b</sup> | 2 (6.5) | 17 (29.3) | 0.014 | 19 (21.3) |
| Use of mechanical ventilation<sup>b</sup> | 1 (3.2) | 13 (22.4) | 0.029 | 14 (15.7) |
| Mortality within 30 days of admission<sup>b</sup> | 0 | 11 (19.0) | 0.007 | 11 (12.4) |
| All-cause mortality within 30 days of admission | 1 (1.6) | 20 (11.4) | 0.018 | 21 (8.8) |
| LRTI<sup>c</sup> (adults: 7 missing values) | 26 (40.6) | 85 (50.6) | 0.188 | 111 (47.8) |
| RSV-attributable pneumonia<sup>b</sup> | 12 (18.8) | 62 (36.9) | 0.008 | 74 (31.9) |
| RSV documented from BAL<sup>b</sup> | 2 (16.7) | 23 (37.1) | 0.024 | 25 (33.8) |
| RSV-bacterial co-infection documented from BAL | 0 | 7 (11.3) | 0.020 | 7 (9.5) |

<sup>a</sup>Refers to patients admitted to hospital for an acute-respiratory-tract infection (ARTI)-attributable hospital admission (i.e excluded patients admitted to hospital for other reasons).<sup>b</sup>Refers to all patients seen in an ambulatory setting or admitted to hospital for their RSV infection or for another reason. BAL: Bonchoalveolar lavage, SD: Standard deviation, LRTI: Lower respiratory tract infection (adults 7 missing values); d: days. RSV-attributable pneumonia (7 missing values)
were significantly more likely to be admitted to hospital for RSV. When stratified by age groups (adults vs. children), increasing age (OR 1.4; 95% CI: 1.0–1.8; \( P = 0.027 \)), patients with solid tumors (OR 5.2; 95% CI: 1.4–20.9; \( P = 0.015 \)) and those requiring any chronic immunosuppression mainly for vasculitis (OR 4.1; 95% CI: 1.1–16.0; \( P = 0.034 \)) when compared to HSCT, remained significant predictors of ARTI-attributable hospital admission among adults. Post-hoc sensitivity analyses did not affect our risk estimates and the above findings (Table 3, Additional file 1: Tables S2, S4 and S6).

Predictors of LRTI and pneumonia

From multivariable analyses, patients presenting with a bacterial co-infection were significantly more likely to present with LRTI (OR 3.4; 95% CI: 1.5–8.2; \( P = 0.005 \)) and pneumonia (OR 3.6; 95% CI: 1.6–8.4; \( P = 0.002 \)). When stratified by age groups (adults vs. children), bacterial co-infection was also an independent and significant predictor for LRTI (OR 3.4; 95% CI: 1.3–9.8; \( P = 0.018 \)) only in adults. Increasing age was also a significant predictor for LRTI (OR 1.1; 95% CI: 1.0–1.3; \( P = 0.048 \)) and pneumonia (OR 1.2; 95% CI: 1.1–1.4; \( P = 0.003 \)) among all patients. Post-hoc sensitivity analyses did not affect our risk estimates and the above findings (Table 4, Additional file 1: Tables S3, S5 and S7).

**Discussion**

Two important observations made in our study were that 1) RSV-infected immunocompromised adults (mainly elderly) presented with more severe outcomes compared to children; and that 2) adult patients with solid tumors or leukemia and those requiring chronic immunosuppression for vasculitis were significantly more likely to be admitted to hospital for RSV disease compared to HSCT recipients.

**Table 3** Predictors for ARTI-attributable hospital admission among all immunocompromised patients and stratified by age-groups (adults vs children)

| Predictor                                | Univariable analyses       | Multivariable analyses       |
|------------------------------------------|---------------------------|----------------------------|
|                                          | OR (95% CI)               | OR (95% CI)               |
| Increasing age (by 10Y range)            |                           |                           |
| All                                      | 1.0 (0.9;1.1)             | 1.0 (0.9;1.2)             |
| Adults                                   | 1.6 (1.3;2.1)             | 1.4 (1.0;1.8)             |
| Children                                 | 0.6 (0.2;1.8)             | –                         |
| Bacterial co-infection                   |                           |                           |
| All                                      | 1.6 (0.8;3.4)             | 1.5 (0.7;3.3)             |
| Adults                                   | 2.2 (0.9;5.2)             | 1.7 (0.6;4.5)             |
| Children                                 | 0.8 (0.2;3.3)             | 1.0 (0.2;4.6)             |
| ALC                                      |                           |                           |
| All                                      | 1.0 (1.0;1.2)             | 1.0 (1.0;1.2)             |
| Adults                                   | 1.0 (1.0;1.2)             | 1.0 (1.0;1.2)             |
| Children                                 | 0.8 (0.5;1.2)             | 0.8 (0.5;1.2)             |
| SOT                                      |                           |                           |
| All                                      | 2.1 (0.9;5.1)             | 1.9 (0.8;4.6)             |
| Adults                                   | 2.1 (0.9;5.4)             | 1.6 (0.6;4.4)             |
| Children                                 | 1.7 (0.1;53.3)            | –                         |
| Leukemia/lymphoma                        |                           |                           |
| All                                      | 4.0 (1.7;9.5)             | 3.9 (1.7;9.7)             |
| Adults                                   | 3.0 (1.0;9.3)             | 1.5 (0.4;5.2)             |
| Children                                 | 7.5 (1.1;149.7)           | –                         |
| Solid tumor                              |                           |                           |
| All                                      | 7.2 (2.6;21.2)            | 7.4 (2.7;21.9)            |
| Adults                                   | 7.4 (2.1;28.4)            | 5.2 (1.4;20.9)            |
| Children                                 | 10.5 (1.2;240.1)          | –                         |
| Chronic immunosuppressive medication     |                           |                           |
| All                                      | 10.5 (3.7;32.9)           | 9.5 (3.3;30.2)            |
| Adults                                   | 8.2 (2.6;28.4)            | 4.1 (1.1;16.0)            |
| Children                                 | 35.0 (2.6;1450.5)         | –                         |
| PID                                      |                           |                           |
| All                                      | 4.3 (0.7–26.1)            | 4.5 (0.7;29.0)            |
| Children                                 | 10.5 (0.8–298.2)          | –                         |

| Absolute lymphocyte counts (ALC), Hematopoietic stem cell recipients (HSCT), Primary immunodeficiency disease (PID) Solid organ transplant (SOT), Acute-respiratory-tract infection (ARTI) |

\( ^a \)N refers to the total number of patients included in all multivariable analyses for whom information on all predictors and outcomes were available. 24 patients (23 adults – 1 child) were excluded from univariable and multivariable analyses because of missing values for nALC.

Limited sample size in the pediatric subset limited the number of predictors, which could be included in multivariable analyses (−).
The overall burden of RSV among health-seeking populations has mostly been evidenced in young children, adults above 65 years of age, pregnant women or immunocompromised patients in whom equivalent disease burden to influenza has been reported [19–21]. The estimation of severe RSV infections in Switzerland is limited by the lack of an active RSV surveillance system. However, from our findings, we estimated that less than 10% RSV

| Table 4 Predictors of progression to LRTI and pneumonia among all immunocompromised patients and stratified by age-groups (adults vs children) |
|---------------------------------------------------------------|
| **Outcome: LRTI N = 215 (152 adults, 63 children)** |
| **Univariable analyses** | **Multivariable analyses** |
| **OR (95%CI)** | **OR (95% CI)** | **P value** |
| **Increasing age (by 10Y range)** | | |
| All | 1.2 (1.0;1.3) | 1.1 (1.0;1.3) | 0.048 |
| Adults | 1.3 (1.1;1.7) | 1.2 (1.0;1.5) | 0.128 |
| Children | 0.9 (0.3;2.8) | – | – |
| **Bacterial co-infection** | | |
| All | 3.3 (1.5;7.5) | 3.4 (1.5;8.2) | 0.005 |
| Adults | 3.2 (1.3;8.6) | 3.4 (1.3;9.8) | 0.018 |
| Children | 3.4 (0.8;17.5) | 4.1 (0.9;24.6) | 0.084 |
| **ALC** | | |
| All | 1.0 (1.0;1.2) | 1.0 (1.0;1.2) | 0.501 |
| Adults | 1.1 (1.0;1.3) | 1.0 (1.0;1.3) | 0.580 |
| Children | 1.0 (0.6;1.4) | 0.9 (0.6;1.3) | 0.457 |
| **Type immunosuppression (compared to HSCT)** | | |
| **SOT** | | |
| All | 0.9 (0.4;1.9) | 0.7 (0.3;1.4) | 0.294 |
| Adults | 1.0 (0.4;2.1) | 0.7 (0.3;1.5) | 0.344 |
| Children | 0.7 (0.1;6.4) | – | – |
| **Leukemia/lymphoma** | | |
| All | 1.0 (0.5;2.0) | 1.0 (0.5;2.3) | 0.935 |
| Adults | 2.0 (0.7;6.0) | 1.2 (0.4;3.9) | 0.791 |
| Children | 0.5 (0.1;2.7) | – | – |
| **Solid tumor** | | |
| All | 1.0 (0.4;2.5) | 1.0 (0.4;2.6) | 0.985 |
| Adults | 1.2 (0.4;3.8) | 0.8 (0.2;2.8) | 0.718 |
| Children | 0.7 (0.1;4.4) | – | – |
| **Chronic immunosuppressive medication** | | |
| All | 3.4 (1.2;10.4) | 2.6 (0.9;8.3) | 0.077 |
| Adults | 4.0 (1.3;15.6) | 2.4 (0.7;10.2) | 0.204 |
| Children | 2.0 (0.22;1.4) | – | – |
| **PID** | | |
| All | 0.6 (0.1;3.1) | 0.7 (0.1;4.3) | 0.724 |
| Children | 0.7 (0.1;6.4) | – | – |

**Outcome: LRTI N = 215 (152 adults, 63 children)**

**Increasing age (by 10Y range)**

| All | 1.2 (1.1;1.4) | 1.2 (1.1;1.4) | 0.003 |

**Bacterial co-infection**

| All | 3.1 (1.5;6.6) | 3.6 (1.6;8.4) | 0.002 |

**ALC**

| All | 1.0 (1.0;1.1) | 1.0 (1.0;1.1) | 0.439 |

**Type immunosuppression (compared to HSCT)**

| **SOT** | | |
| All | 0.7 (0.3;1.7) | 0.5 (0.2;1.1) | 0.094 |
| **Leukemia/lymphoma** | | |
| All | 0.9 (0.4;2.1) | 1.0 (0.4;2.5) | 0.956 |
| **Solid tumor** | | |
| All | 1.2 (0.5;3.2) | 1.3 (0.4;3.6) | 0.639 |
| **Chronic immunosuppressive medication** | | |
| All | 2.0 (0.8;5.4) | 1.4 (0.5;3.8) | 0.540 |
| **PID** | | |
| All | 0.4 (0.0;2.8) | 0.7 (0.0;5.0) | 0.721 |

Absolute lymphocyte counts (ALC); Hematopoietic stem cell recipients (HSCT), Primary immunodeficiency disease (PID); Solid organ transplant (SOT); 

*N refers to the total number of patients included in all multivariable analyses for whom information on all predictors and outcomes was available. 24 patients (23 adults – 1 child) were excluded from univariable and multivariable analyses because of missing values for ALC. Limited sample size in the pediatric subset limited the number of predictors which could be included in multivariable analyses for the outcome LRTI (*).
positive samples were collected from immunocompromised subjects, thus suggesting either that RSV only affects a very small subset of immunocompromised patients or insufficient diagnostic screening [6, 11, 22, 23].

We have documented important differences in outcomes of RSV infections among immunocompromised children compared with immunocompromised adults. While children were more frequently admitted to hospital for their RSV infection compared to adults, most patients admitted to the ICU, requiring invasive ventilation or those who died were adults, thus suggesting worse outcomes among our adult inpatients. In addition, elderly patients were significantly more likely to present with pneumonia compared to children. Furthermore, as supported in another study [6], over one third of our RSV-infected immunocompromised adult cohort presented with pneumonia for whom a transfer to the ICU was required resulting in mortality rates of almost 20%. These important findings highlight the potential consequences of RSV infection among adults with underlying immunodeficiencies and may suggest that these patients would specifically benefit from preventive strategies.

As suggested in another study [6], bacterial co-infection also contributed undoubtedly to progression towards LRTI and pneumonia, likely as a result of RSV-induced injuries to respiratory epithelium thereby increasing bacterial adherence [11, 24, 25].

Studies focusing on the severity of viral co-infections have resulted in different findings likely as a result of including various age groups and breadth of illness severity and limited sample sizes [22, 26, 27]. While viral co-infections were documented among one-third of our pediatric patient-population and 20% of the adult one, no significant association between viral co-infections and our outcomes of interest were documented, in line with findings from a recent systematic review [28]. Furthermore, post-hoc sensitivity analyses excluding patients with viral co-infections did not affect our risk estimates.

The burden of RSV infections has been widely and consistently evidenced among HSCT recipients, with much less known in other immunocompromised patient populations [6, 9, 11]. Some studies [29, 30] reported severe RSV outcomes among SOT recipients and children with congenital immunodeficiencies, without being consistent throughout the literature [31]. To our knowledge, this is the first report showing that adult patients requiring chronic immunosuppression mainly for Connective Tissue Disease (CTD) or vasculitis and those with solid tumors were at highest risk for hospital admission when compared to HSCT recipients. Furthermore, discrepancies between our findings and those in published literature were not influenced by timing after transplantation as post-hoc sensitivity analyses excluding HSCT recipients infected 2 years after their transplantation, did not affect our risk estimates. We also reported increased severity of RSV infections among patients with leukaemia in line with published literature [32, 33]. These important findings highlight the burden of RSV disease among various categories of immunocompromised patients other than HSCT recipients.

Important strengths of our study include a large variety of immunocompromised adults and children categorized in 6 mutually exclusive categories. All subgroup analyses were defined a priori and post hoc sensitivity analyses confirmed robustness of the results. The inclusion of outpatients enabled the use of hospital admission as a measure of clinical severity in addition to LRTI and pneumonia thus supporting consistency of our findings. Potential limitations of our study relate to its retrospective design and laboratory-based collected data, which may have led to selection bias. However all consecutive immunocompromised patients with URT or LRT symptoms were systematically tested for respiratory viruses according to local guidelines, which may have reduced the risk of selection bias. Second, the inclusion of adults and children and the lack of adjustment for other comorbidities, may have biased our findings towards more severe outcomes among adults, as children are routinely screened for RSV infections whereas adults are swabbed for RSV while experiencing more severe symptoms. However, half of our adult RSV-positive cohort was screened in an ambulatory setting while consulting with mild symptoms and sensitivity analyses excluding children detected by rapid antigen assays did not affect our risk estimates. As such, we believe, that our findings were still suggestive of worse clinical outcomes in RSV-infected immunocompromised adults. Third, our estimation of bacterial co-infections may have been underestimated as BAL are rarely performed in children and pneumonia rarely results in positive blood cultures. Finally, the lack of a comparator group of patients without any other identified pathogen would have better delineated the attribution of disease burden solely to RSV.

Conclusions
In conclusion, our study conducted on a small sub-set of patients, suggests a higher burden of RSV disease in immunocompromised adults compared to children, more specifically among patients with solid tumors, leukaemia/lymphoma or those requiring chronic immunosuppression for CTD or vasculitis.

Additional file

Additional file 1: Figure S1. Flow diagram. Table S1. Description of long-term immunosuppression treatment population. Table S2. Predictors for ARTI-attributable hospital admission among all immunocompromised patients and stratified by age-groups (adults vs. children). Table S3. Predictors of progression to LRTI and pneumonia among all immunocompromised patients.
and stratified by age-groups (adults vs. children). Table S4. Predictors for ARTI-attributable hospital admission among all immunocompromises patients and stratified by age-groups (adults vs. children). Table S5. Predictors of progression to LRTI and pneumonia among all immunocompromises patients and stratified by age-groups (adults vs. children). Table S6. Predictors for ARTI-attributable hospital admission among all immunocompromised patients and stratified by age-groups (adults vs. children). Table S7. Predictors of progression to LRTI and pneumonia among all immunocompromised patients and stratified by age-groups (adults vs. children). (DOXX 140 kb)

Abbreviations
ALC: Absolute lymphocytic count; ANC: Absolute neutrophil count; ARTI: Acute-respiratory-tract infection; CLADE: Chronic lung allograft dysfunction; CTD: Connective Tissue Disease; HIV: Human immunodeficiency virus; HSCT: Hematopoietic stem cell transplant; LRTI: Lower respiratory tract infection; PID: Primary immunodeficiency disease; RSV: Respiratory syncytial virus; SOT: Solid organ transplant; URTI: Upper respiratory tract infection

Acknowledgements
Not applicable.

Funding
No financial support was obtained for this study.

Availability of data and materials
The Data is available upon request. Dr. Sandra A. Asner, the corresponding author should be contacted to request the data.

Authors’ contributions
SAA designed the study; OC and SD collected data; OC, SD and SAA wrote the article; SAA and JP analyzed data; SAA and KMPB interpreted the data. OC, SD, SAA, KMPB, JP, PM, OM, JDA, SML, MA, MBP and LK critically revised the manuscript for important intellectual content and gave final approval for this version to be published.

Ethics approval and consent to participate
The local ethics committees (REB) of Lausanne (CER-VD 86/15) and Geneva (CCER GE 15–085) approved this study and they waived the requirement for obtaining informed consent.

Consent for publication
Not applicable.

Competing interests
Olga Chatzis, Stephanie Darbre, Jerome Pasquier, Pascal Meylan, Oriol Manuel, John David Aubert, Maja Beck-Popovic, Stavroula Masouridi-Levrat, Marc Ansari, Laurent Kaiser MD and Klara M. Posfay-Barbe have no conflicts of interest to declare. Sandra A. Asner received an educational Grant from Abbvie Switzerland.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Paediatric Infectious Disease Unit, Division of General Paediatrics, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland. 2 Department of Paediatrics, Paediatric Infectious Disease Unit, University Hospital of Lausanne, Lausanne, Switzerland. 3 Institute of Social and Preventive Medicine (IUMSP), University of Lausanne, Lausanne, Switzerland. 4 Department of Laboratories, Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland. 5 Department of Medicine, Infectious Diseases Service, University Hospital of Lausanne, Lausanne, Switzerland. 6 Department of Pulmonary transplantation, Pulmonology Service, University Hospital of Lausanne, Lausanne, Switzerland. 7 Department of Paediatrics, Paediatric Hematology and Oncology Unit, University Hospital of Lausanne, Lausanne, Switzerland. 8 Department of Oncology, Hematology Service, University Hospital of Geneva, Geneva, Switzerland. 9 Department of Pediatrics, Pediatric Infectious Disease Unit, CHUV, Rue du Bugnon 46, 1011 Lausanne, Switzerland.

Received: 6 July 2017 Accepted: 20 February 2018
Published online: 06 March 2018

References
1. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev. 2009;10(3):148–53.
2. Hall CB, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315(2):27–81.
3. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917–28.
4. Fallaye AR, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–59.
5. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001;33(6):792–6.
6. Voller C, et al. Respiratory viral infection-associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis. 2014;14:665.
7. Lanari M, et al. Respiratory syncytial virus infections in infants affected by primary immunodeficiency. J Immunol Res. 2014;2014:850831.
8. Aebi CEA. Consensus concernant la prévention des infections par le virus respiratoire syncitial (VRS) avec l’anticorps humanisé monoclonal palivizumab (Synagis). Paediatrica. 2004;15(6):17–9.
9. Khanna N, et al. Respiratory syncytial virus infection in hematopoietic cell transplant patients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2008;198(4):402–12.
10. Ljungman P, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the infectious diseases working Party of the European Group for blood and marrow transplantation. Bone Marrow Transplant. 2001;28(5):479–84.
11. Kim YJ, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195–204.
12. Shah DP, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood. 2014;123(21):3263–8.
13. Jonckheere S, et al. Multicenter evaluation of BD Veritor system and RSV Xpert(R) flu/RSV XC assay for rapid detection of influenza a, influenza B, and respiratory syncytial virus. Diagn Microbiol Infect Dis. 2015;83(1):37–40.
14. Franz A, et al. Correlation of viral load of respiratory pathogens and co-infections with disease severity in children hospitalized for lower respiratory tract infection. J Clin Virol. 2010;48(4):239–45.
15. Regamey N, et al. Viral etiology of acute respiratory infections with cough in infancy: a community-based birth cohort study. Pediatr Infect Dis J. 2008;27(2):100–5.
16. Salez N, et al. Prospective and retrospective evaluation of the Cepheid Xpert(R) flu/RSV Xpert(R) assay for rapid detection of influenza a, influenza B, and respiratory syncytial virus. Diagn Microbiol Infect Dis. 2015;81(4):256–8.
17. Memel LA, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1–45.
18. Martin ET, et al. Multiple versus single virus respiratory infections: viral load and clinical disease severity in hospitalized children. Influenza Other Respir Viruses. 2012;6(1):71–7.
19. Kamigaki T, et al. Estimates of influenza and respiratory viral syncytial virus infections with fraction modeling approach in Baguio City, the Philippines, 2012-2014. Influenza Other Respir Viruses. 2017;11(4):311–8.
20. Emukule GO, et al. Estimating influenza and respiratory viral syncytial virus-associated mortality in western Kenya using health and demographic surveillance system data, 2007-2013. PLoS One. 2017;12(7):e0180890.
21. Duppenthaler A, et al. Low incidence of respiratory viral syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child. 2004;89(10):961–5.
22. Pastula ST, et al. Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infect Dis. 2017;4(1):ofw270.
23. Modjarrad K, et al. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23-24 March 2015. Vaccine. 2016;34(2):190–7.
24. Hament JM, et al. Direct binding of respiratory syncytial virus to pneumococci: a phenomenon that enhances both pneumococcal adherence to human epithelial cells and pneumococcal invasiveness in a murine model. Pediatr Res. 2005;58(6):1198–203.
25. Boeckh M, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44(2):245–9.
26. Asner SA, et al. Is virus coinfection a predictor of severity in children with viral respiratory infections? Clin Microbiol Infect. 2015;21(3):264 e1–6.
27. Top FH Jr, Connor EM, Carlin DA. Prophylaxis against respiratory syncytial virus in premature infants. Impact-RSV Study Group. Lancet. 2000;355(9208):1014.
28. Asner SA, et al. Clinical disease severity of respiratory viral co-infection versus single viral infection: a systematic review and meta-analysis. PLoS One. 2014;9(6):e99922.
29. Asner S, et al. Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children. Pediatr Infect Dis J. 2013;32(10):1073–6.
30. Navas L, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr. 1992;121(3):348–54.
31. Chu HY, et al. Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children. Influenza Other Respir Viruses. 2016;10(3):205–10.
32. Santos RP, et al. The use of intravenous palivizumab for treatment of persistent RSV infection in children with leukemia. Pediatrics. 2012;130(6):e1695–9.
33. Shachor-Meyouhas Y, et al. Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department. J Pediatr Hematol Oncol. 2013;35(2–5 years2):124–8.